Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geogr... Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. Mehr anzeigen
— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted...
Six Late-Stage Programs with Peak Revenue Potential of $10B - $20B1 Poised to Deliver Sustainable Growth Expected Phase 3 Data Readouts in 2025 for Oveporexton (TAK-861), Zasocitinib (TAK-279...
− Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and...
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several...
Umsatzwachstum von +13,4 % zu aktuellen Wechselkursen (AER); +5,0 % zu konstanten Wechselkursen (CER) Getrieben durch die kontinuierliche Weiterentwicklung von Wachstums- und...
Croissance du chiffre d’affaires de +13,4 % à taux de change réels (TCR) ; +5,0 % à taux de change constants (TCC) grâce à la progression continue des produits de croissance et de lancement...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a...
売上収益は、実勢レート（AER：Actual Exchange Rate）ベースで対前年同期+13.4%、恒常為替レート（CER：Constant Exchange Rate）ベースで同+5.0%成長し、引き続き成長製品・新製品の伸長が牽引（CERベースで...
Revenue Growth of +13.4% at Actual Exchange Rates (AER); +5.0% at Constant Exchange Rate (CER) Driven by Continued Advancement of Growth & Launch Products (+18.7% at CER) Core Operating...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.22 | -1.65165165165 | 13.32 | 13.42 | 12.98 | 1635225 | 13.17480327 | DR |
| 4 | -0.36 | -2.67459138187 | 13.46 | 14.03 | 12.98 | 1544100 | 13.50854815 | DR |
| 12 | -1.34 | -9.27977839335 | 14.44 | 14.485 | 12.98 | 1660087 | 13.77699257 | DR |
| 26 | 0.3 | 2.34375 | 12.8 | 15.08 | 12.775 | 1899117 | 13.9330302 | DR |
| 52 | -0.93 | -6.62865288667 | 14.03 | 15.08 | 12.575 | 1803731 | 13.94512334 | DR |
| 156 | -0.63 | -4.58849235251 | 13.73 | 17.15 | 12.28 | 2255381 | 14.52061138 | DR |
| 260 | -6.93 | -34.5981028457 | 20.03 | 20.6 | 12.28 | 2146011 | 15.44131437 | DR |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
